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Background:Cellular uptake of small peptides is an important physiological processmediated by the PTR family of
proton-coupled peptide transporters. In bacteria peptides can be used as a source of amino acids and nitrogen.
Similarly in humans peptide transport is the principle route for the uptake and retention of dietary protein in
the form of short di- and tri-peptides for cellular metabolism.
Scope of the review: Recent crystal structures of bacterial PTR family transporters, combined with biochemical
studies of transport have revealed key molecular details underpinning ligand promiscuity and the mechanism
of proton-coupled transport within the family.
Major conclusions: Pairs of salt bridge interactions between transmembrane helices work in tandem to
orchestrate alternating access transport within the PTR family. Key roles for residues conserved between
bacterial and eukaryotic homologues suggest a conserved mechanism of peptide recognition and transport
that in some cases has been subtly modiﬁed in individual species.
General signiﬁcance: Physiological studies on PepT1 and PepT2, the mammalian members of this family, have
identiﬁed these transporters as being responsible for the uptake of many pharmaceutically important drug
molecules, including antibiotics and antiviral medications and demonstrated their promiscuity can be used for
improving the oral bioavailability of poorly absorbed compounds. The insights gained from recent structural
studies combinedwith previous physiological and biochemical analyses are rapidly advancing our understanding
of this medically important transporter superfamily. This article is part of a Special Issue entitled Structural
biochemistry and biophysics of membrane proteins.
© 2014 The Author. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Main article
Peptide transport is one of the main routes through which cells ob-
tain nitrogen and amino acids formetabolism and growth [1,2]. In bacte-
ria at least three different systems have been identiﬁed that actively
uptake peptides from the periplasm across the inner membrane into
the cytoplasm. These include the Opp and Dpp systems that belong to
the ATP Binding Cassette (ABC) transporter family [3,4], the oligopeptide
transporters [5] and the peptide transporter or PTR family [6]. This re-
view focuses on the PTR family (pfam00854), which in contrast to the
Opp and Dpp systems are members of the Major Facilitator Superfamily
(MFS) of secondary active transporters and are also referred to as the
POT or proton dependent oligopeptide transporter family [7]. Unlike
the other peptide transport systems the PTR family are the only mem-
bers to have homologues in mammalian genomes [8]. Remarkably PTR
members in plants, which are clustered with the nitrate transporter 1,biochemistry and biophysics of
. This is an open access article underor NRT1 family, have evolved to recognize and transport other nitroge-
nous ligands including nitrate, the plant hormone auxin and glucosino-
late compounds used for seed defense against insect predation [9].
Although the Opp, Dpp and PTR systems are structurally and
functionally distinct, they do all share one common feature — substrate
promiscuity. Any system whose function is to transport peptides from
the environment for nutritional assimilation should, by necessity not
be too speciﬁc for certain sequences so as to avoid restricting uptake
to only a subset of the available peptides. Unsurprisingly, early studies
on the periplasmic binding proteins from the Opp ABC transporters dis-
covered that these proteins could indeed recognize a diverse range of
peptides [10]. This promiscuity is also observed in the PTR family [11].
However, there exists a key functional difference between these two
systems.Whereas in the Opp system transport is driven by the hydroly-
sis of ATP, essentially decoupling peptide recognition from the driving
force for transport, within the PTR family peptide binding and recogni-
tion are intimately coupled with proton binding and transport. The
molecular basis for how a single binding site can be both highly promis-
cuous with respect to peptide recognition, while retaining a conservedthe CC BY license (http://creativecommons.org/licenses/by/3.0/).
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research with important implications for understanding the nature of
binding promiscuity in nutrient transporters.
In humans peptide uptake via the PTR transporters PepT1 and PepT2
is the main route through which the body absorbs and retains dietary
protein [8,12,13]. Ingested protein is broken down into peptide frag-
ments and free amino acids through acid hydrolysis in the stomach
and the action of non-speciﬁc peptidases in the small intestine. The re-
sultant peptides are then actively transported across the intestinal
brush border membrane through PepT1 [14–18]. Peptide transport
also occurs at the renal epithelium in the kidney, where PepT2, a func-
tionally related paralogue of PepT1 reabsorbs peptides from the glomer-
ular ﬁltrate [19,20]. It is estimated that PepT1 and PepT2 can recognize
and transport N7000 different combinations of di- and tri-peptides,
making them some of the most promiscuous transporters in biology
[1,21,22].
The ﬁrst PepT1 gene was cloned from a rabbit cDNA library in 1994
[15]. The primary structure of PepT1 and PepT2 predicted 12 transmem-
brane (TM) spanning alpha helices [14]. PepT1 and PepT2 exhibit differ-
ent kinetic properties; PepT1 is a high capacity, broad speciﬁcity
transporter with KM values in the low mM range for most di-and
tripeptides [17] whereas PepT2 exhibits higher afﬁnity for peptides
with KM values in low μM range and also appears to be more selective
with respect to side chain accommodation [19]. This difference has
been postulated to facilitate the role these two proteins play, with
PepT1 being responsible for rapid peptide uptake in the small intestine
following food ingestion, whereas PepT2must bemore efﬁcient in pep-
tide recognition to avoid loss of these nutrients in the urine.
In addition to dietary peptide absorption, PepT1 and PepT2 also rec-
ognize several important families of drug compounds that exhibit a ste-
ric resemblance to peptides. These include the commonly prescribed β-
lactam antibiotics cefadroxil and cefalexin [23–25]. In recent years
signiﬁcant attention has been focused on the promiscuity of both
PepT1 and PepT2 as drug delivery vehicles to improve the uptake of
poorly absorbed or retained medications [26]. In vivo studies in mice
have shown convincing evidence that PepT1 and PepT2 substantially
improve the bioavailability of molecules that have been modiﬁed
through the attachment of either a single amino acid or di-peptide to
create so called peptide pro-drugs [27,28]. These modiﬁed drug
molecules exhibit more favorable oral bioavailability proﬁles and may
represent an important tool in the development of more effective med-
ications [29–32]. However a detailed understanding of the mechanism
by which peptide transporters both recognize and transport natural
peptides and their related drug molecules is currently absent and one
of the major intellectual driving forces for their continued study
[33–38].
PTR family transporters belong to the Major Facilitator Superfamily
(MFS) [39] and are proton (H+) driven symporters, using the inwardly
direct proton electrochemical gradient (ΔμH+) to drive the uptake of
peptides across the cell membrane [40,41]. The stoichiometry of proton
driven peptide transport is currently unknown for the bacterial mem-
bers of the family. However, evidence from electrophysiological studies
on rabbit PepT1 expressed in Xenopus laevis oocytes suggests a 2:1 pro-
ton to anionic dipeptide stoichiometry [42]. These studies also propose
that anionic dipeptides are transported in their neutral and negatively
charged forms, with high (μM) and low (mM) afﬁnity respectively. Cat-
ionic dipeptides by contrast are transported in neutral and positively
charged forms. Interestingly, similar studies on PepT2 suggest a 2:1
and 3:1 proton:peptide stoichiometry for neutral and anionic dipep-
tides [43]. These results indicate a mechanistically important link be-
tween the ionization state of the peptide and the interaction with the
transporter, which may have important implications for the design of
drugs to utilize these systems for improved uptake.
At the primary structure level there exists a remarkably high degree
of sequence conservation within the TM helices of the PTR family [6,44]
(Fig. 1). Three sequence motifs have been identiﬁed, one of which isreferred to as the ExxERFxYY motif on TM1. The second two motifs, re-
ferred to as the PTR2-1 and PTR2-2 are less well conserved but are nev-
ertheless clearly present throughout the family [6,7,45]. All three motifs
are locatedwithin theﬁrst 180–250 amino acids of PTR transporters and
point mutations introduced into these regions typically result in inac-
tive proteins [25,46–50]. Several additional conserved residues have
also been shown to affect peptide transport in site directedmutagenesis
studies with PepT1 and also cluster within the ﬁrst six TM helices. A
cluster of tyrosine residues (Tyr 64, 91 and 167) play an important
role in affecting either the Vmax or KM of transport [23,25], whereas a
conserved tryptophan (Trp294) part of the conserved FWALF motif in
TM7, when mutated to an alanine affects both simultaneously [27]. Of
the charged residues only one has been identiﬁed that is essential for
transport, Glu595 in TM10. Within the mammalian POT family there
exist four histidine residues, His57, 111, 121 and 261. Of these only
His57 is essential for PepT1 function and is predicted to be the site of ini-
tial protonation during transport [29]. Many of these residues are pres-
ent in the bacterial homologues of PepT1 and PepT2, and as discussed
below play similarly important roles in proton coupled peptide trans-
port. This conservation between prokaryotic and eukaryotic PTR family
members highlights the remarkable degree of the mechanistic conser-
vation within this family of transporters [8].
The ﬁrst crystal structure of a PTR transporter from the bacterium
Shewanella oneidensis, PepTSo, was determined in 2011, revealing a
novel occluded conformation for theMFS [40]. Thiswas quickly followed
by threemore structures, all from different bacterial species. PepTSt from
Streptococcus thermophilus [49], GkPOT from Geobacillus kaustophilus
[51] and PepTSo2, a second PTR transporter from S. oneidensis [52]. The
last two structures were obtained in complex with an antibacterial
phosphono di-peptide, alafosfalin, and revealed key structural insights
into peptide recognition. We are now uniquely placed to develop a
mechanistic understanding of proton coupled peptide transport in this
highly conserved and physiologically important transporter family.
2. Crystal structures of bacterial members of the PTR family reveal a
conserved binding site for peptides
To date a total of four different PTR family transporters have had
their structure determined by X-ray crystallography from different bac-
terial species (Fig. 2). The four structures represent three unique states
of the transport cycle. PepTSo, theﬁrst structure determined, revealed an
occluded state, where the central peptide binding site had closed
around an unidentiﬁed molecule obtained during puriﬁcation or crys-
tallization (PDB: 2XUT). In contrast, the second structure determined
for this family PepTSt, was captured in the fully open state, with the
binding site accessible to the cytoplasmic side of the membrane — a so
called inward open state (PDB: 4APS). The third and fourth structures
determined were those of GkPOT and PepTSo2 respectively, and were
captured in the inward open state but with a bound peptide sitting in
the peptide binding site (PDB: 4IKZ and 4LEP respectively). GkPOT
was further crystallized in the inward open apo state and with a sulfate
ion bound in the central cavity (PDB: 4IKV, 4IKX, 4IKY & 4IKW) and un-
like the other proteins was crystallized in the lipidic cubic phase, which
allowed diffraction data to be collected at much higher resolution, 1.9 Å
for the apo structure and 2.4 Å for the peptide bound complex [51].
The structures revealed the canonical MFS fold with the N- and C-
terminal six-helix bundles, formed by TM helices TM1–TM6 and TM7–
TM12, coming together in themembrane to forma ‘V’ shaped transport-
er, related by a pseudo two-fold symmetry axis running perpendicular
to the membrane plane [53]. The current POT family structures all
have two additional TM helices, which we termed HA and HB that are
inserted into the cytoplasmic loop connecting the N- and C-terminal
bundles [40]. These form a hairpin in the membrane that packs against
the periphery of the protein, although the arrangement is slightly differ-
ent between the four structures. Their role is currently unclear but these
structures do reveal how the canonical 12 TM MFS fold, observed
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Fig. 1. A. Sequence alignment and secondary structure of PepTSo. Amino acid sequence alignment of S. oneidensis PepTSo (Uniprot: Q8EKT7), S. thermophilus PepTSt (Q5M4H8),
G. kaustophilus GkPOT (Q5KYD1), S. oneidensis PepTSo2 (QHE8ES) with human PepT1 (B2CQT6) and PepT2 (Q16348) homologues using ClustalW. Identical residues are highlighted in
red. The α-helices in PepTSo are depicted as coils above the sequences. The conserved signature motifs within the PTR family are marked with orange horizontal bars. Residues described
in the review are highlighted; proton binding (green triangles), peptide transport (yellow ovals), peptide speciﬁcity (gold stars) and extracellular and intracellular gate (blue squares). The
horizontal blue bar represents the location of the extracellular domain present in the mammalian homologues but absent in the prokaryotic members. B. Topology diagram of human
PepT1 with helices colored blue to red including the position of the extracellular ecto domain between TM9 and 10. The locations of the conserved sequence motifs within the TM helices
are shown. Sequence logos (http://weblogo.berkeley.edu/) of these motifs generated from 24 eukaryotic and 19 prokaryotic PTR family sequences aligned as described for human PepT1
and PepT2 are illustrated.
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can accommodate additional helices. The absence of these helices in
the fungal, plant and mammalian protein sequences however, suggests
they do not contribute to a conserved transportmechanism and are spe-
ciﬁc for the prokaryoticmembers of the family, perhaps playing a role in
stability or folding speciﬁc to these species.
The structure of PepTSo revealed two hydrophilic cavities. A large
central cavity situated within the centre of themembrane and a smaller
extracellular cavity located at the interface between the N- and C-
terminal domains (Fig. 2) [40]. It is roughly cone-shaped, with theapex at the bottomnear the central cavity, opening outward. The overall
dimensions of the small cavity are approximately 16 × 8× 8Å, too small
to accept a peptide though hydrophilic enough to accommodate water
molecules. The role of the extracellular facing cavity is currently unclear,
but as discussed below it forms as a result of structural ﬂexibility within
the C-terminal bundle brought about through the occlusion of an un-
known molecule within the central peptide binding site. We currently
suspect this cavity may be involved in the transport mechanism, possi-
bly as a route for proton binding to residues within the central peptide-
binding site.
Fig. 2. Crystal structures of PTR family transporters. Four crystal structures of PTR/POT family transporters have been determined to date. These represent three unique states in the
alternating access transport cycle; ligand bound occluded (PepTSo), ligand bound inward open (PepTSo2 & GkPOT) and ligand free inward open (PepTSt & GkPOT), shown here in ribbon
representation colored from theirN-terminus (blue) to C-terminus in their respective states in a simpliﬁedmodel of the alternating access transport cycle. The PDB codes for each structure
are given in parentheses.
Fig. 3. Structure of GkPOTE310Q bound to the phosphonopeptide alafosfalin. A. View through a section of the protein volume in the plane of the membrane showing the central peptide
binding site (dashed box) and alafosfalin peptide in sticks. B. Close up view of the binding site rotated 90° to the view in A. Hydrogen bonds between the binding site residues and
alafosfalin peptide are shown as magenta dashed lines. The chemical structure of alafosfalin illustrates the similarities and differences to naturally occurring peptides.
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respectively, were determined in the presence of an antibacterial
phosphono di-peptide, alafosfalin to 2.4 Å and 3.2 Å resolution respec-
tively [51,52]. Alafosfalin had been used previously to study transport
in PepT1 and PepT2 and closely resembles a natural peptide, except
the carboxy group is replaced by a phosphonate moiety [54]. In both
structures the alafosfalin peptide can be seen coordinated within the
central peptide binding site observed previously in PepTSo and PepTSt
(Fig. 3). The binding site itself is formed by residues from TM1, TM2,
TM4 and TM5 from the N-terminal six-helix bundle and from TM7,
TM8, TM10 and TM11 from the C-terminal bundle. Intriguingly howev-
er the alafosfalin sits in slightly different positions in the two structures.
In GkPOT the alafosfalin peptide sits at the apex of an elongated cone
shaped cavity (approximate dimensions 11 Å × 11 Å × 21 Å) that ex-
tends out from the centre of the transporter and opens out at the cyto-
plasmic end of the molecule (Fig. 3A). The complex of alafosfalin with
GkPOT was achieved by mutating a key acidic residue, Glu310 on TM7
to glutamine. The authors propose that Glu310 plays a key role in the
proton coupling mechanism in GkPOT and its mutation to glutamine
is proposed to mimic the protonated state of the transporter [51].
The peptidemakes a number of interactions to conserved residues in
the peptide binding site; the phosphonate group, which is analogous to
the carboxy terminus, forms hydrogen bonds with the side chain of
the mutated Glu310, and with the hydroxyl group of Tyr40 and
guanidiniumgroup of Arg43 on TM1. As such the peptidemakes a direct
link between twohelices in each of the six TMbundles. Tyr40 forms part
of a highly conserved sequencemotif, ExxERFxYY on TM1(Fig. 1). At the
opposite end of the peptide the N-terminal amino group is recognized
by Asn342 on TM8 and Glu413 on TM10. Glu413 is equivalent to
Glu595 in the human PepT1 transporter, and appears to be an essential
component of the transport mechanism. Mutation of this residue in any
PTR family transporter so far tested results in complete loss of transport
[49,51,55], underlining the importance of this acidic side chain in the
transport mechanism. The GkPOT structure revealed additional space
on the C-terminal side of the peptide molecule, which was speculated
may accommodate a third amino acid residue in the case of tri-
peptide binding. The arrangement of opposite charges within the bind-
ing sitemay play an important role in the recognition and orientation of
peptides. Indeed, a similar arrangement of charges was observed in theFig. 4. Structure of PepTSo2 bound to the phosphonopeptide alafosfalin. A. View through a sectio
site (dashed box) and alafosfalin peptide in sticks. B. Close up view of the binding site rotated 9
tide are shown as magenta dashed lines.periplasmic binding protein OppA from Salmonella enterica serovar
Typhimurium andDppA from Escherichia coli [56,57], where salt bridges
to the peptide amino and carboxy termini at either end of the binding
cavity act to ﬁx peptides of speciﬁc length. Perhaps a similarmechanism
operates within the PTR family to preferentially bind di- and tri-
peptides as previously suggested [58]. The presence of several possible
hydrogen-bond donors and acceptors could also be advantageous in
adapting to peptides of various lengths, sequences and charges, as ob-
served in the OppA proteins [59]. Most of the other residues in the bind-
ing site are conserved hydrophobic residues, including Ile165, Trp306,
Trp440 and Phe441. These residues are likely to provide a suitable envi-
ronment for peptide side-chains that in general are more hydrophobic
than the peptide backbone.
By comparison, in the PepTSo2 structure the position of the
alafosfalin is slightly different, with the peptide displaced approximate-
ly 3.5 Å towards the cytoplasmic side of the transporter (Fig. 4). Interac-
tions to the binding site residues are still similar to the GkPOT complex,
although differences are apparent. The phosphono group is positioned
to form a hydrogen bond to Tyr29 and salt bridge to Arg25. These are
equivalent to Tyr40 and Arg36 in GkPOT. In PepTSo2 therefore, the pep-
tide is positioned to interact with the equivalent tyrosine on TM1 but
has switched to the arginine in the ExxERFxYY motif. The reason for
this appears simple; the equivalent arginine to Arg43 in GkPOT is absent
in PepTSo2, replaced by a glutamine, Gln32. On the opposite side of the
binding site, the amino terminus of the peptide sits in a narrow polar
pocket formed by Asn151, Asn329 and Glu402. As observed in the
GkPOT structure, the amino terminus is recognized through hydrogen
bonds to Asn329 and Glu402, which is equivalent to Glu413 in GkPOT
and Glu595 in human PepT1, so again we observe further evidence for
a role of this glutamate in coordinating the amino terminus of peptides
within the binding site of these proteins. Functional data in the formof a
thermal stabilization assay was used to conﬁrm the importance of
Arg25 andGlu402 in peptide recognition in PepTSo2, with alaninemuta-
tions abolishing the stabilization seen in the presence of di- and tri-
peptides in the WT protein [52].
Comparing the two structures reveals a number of interesting obser-
vations (Fig. 5). An acidic residue equivalent to Glu300 in GkPOT is
found in this region of TM7 in the majority of PTR family members, in-
cluding the mammalian PepT1 and PepT2 proteins (Fig. 1). Transportn of the protein volume in the plane of themembrane showing the central peptide binding
0° to the view in A. Hydrogen bonds between the binding site residues and alafosfalin pep-
A B
Fig. 5. Structural comparison of the alafosfalin binding site between GkPOTE310Q and PepTSo2. A. Binding site of both GkPOT (colored residues) and PepTSo2 (gray residues) is shown. The
areas that differmost are highlighted by the dashedmagenta ovals. B. View rotated 90°with TM8 removed for clarity. The black arrow indicates the displacement of the alafosfalin peptide
(~2 Å) in GkPOT relative to that in PepTSo2.
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an important role in coupling peptide transport to the electrochemical
proton gradient [49], and where present is essential for transport [49,
51,55,60]. In PepTSo2 however the equivalent residue to Glu300 is a glu-
tamine (Gln290) and the crystal structure reveals no acidic residue is
located nearby to cover the role of this residue in proton binding. In-
stead a tyrosine side chain, Tyr291, sits in a similar place in TM7 and
as discussed above is positioned within hydrogen bonding distance to
the carbonyl of the alafosfalin peptide (Fig. 4). It is unclear what the
mechanistic implications for this are in PepTSo2, but given the essential
role of equivalent acidic residues in this region of TM7 in other PTR fam-
ily transporters it appears possible that PepTSo2 may operate using a
modiﬁed proton coupling mechanism.
Another difference is the position of alafosfalin in the binding site. In
PepTSo2 the peptide is noticeably shifted in favor of interactions with
TM1, 7 and 8 and sits ~2 Å further down into the cavity than the
alafosfalin in GkPOT. In GkPOT additional interactions are observed
with TM5, the result of the conserved tyrosine on this helix, Tyr78mov-
ing into the binding site to contact the peptide (highlighted in Fig. 5). In
both structures the conserved glutamate on TM10 (Glu413 and Glu402
on GkPOT and PepTSo2 respectively) have slightly different interaction
partners. While in GkPOT Glu413 forms a hydrogen bond to an aspara-
gine, Asn342 on TM8, which in turn contacts the alafosfalin peptide
through a hydrogen bond to the amino terminus. In PepTSo2 the gluta-
mate on TM10, Glu402, interacts with a tyrosine on TM5, Tyr147,
linking these two helices together. Interestingly, GkPOT also contains a
tyrosine at this position, Tyr162, except in the current structures this
side chain adopts a different rotamer position and points away from
the peptide-binding site.
The subtle implications of these differences with respect to the
mechanism of transport in GkPOT, PepTSo2 and the wider PTR family
are currently difﬁcult to determine. Further biochemical studies will
be required to delineate the extent to which these differences represent
modiﬁcations to a fundamental mechanism of proton coupled peptide
transport in these proteins, orwhether somemembers of the PTR family
have evolved different mechanisms using similar arrangements of side
chains within the binding site.
3. Protonation sites in the peptide binding site
PTR family transporters are proton coupled, using the inwardly di-
rected H+ electrochemical gradient (ΔμH+; interior negative or alkaline)
[15,61]. As such there must exist speciﬁc sites of proton binding thatfacilitate the uptake and release of peptides. In the GkPOT study the
ﬁrst crystal structure was obtained with a sulfate ion coordinated in
the same position as the phosphono moiety of the peptide, i.e. coordi-
nated to Glu310 (Fig. 3) [51]. The 2.0 Å resolution of this crystal struc-
ture ensured the accuracy of the observation (PDB: 4IKW). Given the
low pKa value for sulfate it was reasonable to suggest the side chain of
Glu310 should be protonated in this structure. Supporting this assign-
ment, a further complex of sulfate with the Glu310Gln, which would
mimic the protonated state of the glutamate side chain, showed identi-
cal interactions. This observation suggests that in the current conforma-
tion of the transporter Glu310 has an abnormally high pKa value and is
likely to play an important role in the proton couplingmechanism. Var-
ious mutants of the equivalent glutamate in PepT1, Glu419 have been
reported to drastically reduce transport activity, exceptwheremutation
was to an aspartatic acid [60], indicating the importance of a negatively
charged residue at this position in the mammalian proteins. Supporting
this, mutation of the equivalent glutamate in PepTSt also results in loss
of transport [49].
Biochemical assays on both PepTSt and GkPOT have been reported
that also provide additional clues as to the function of conserved side
chains in the binding site. Using a combination of proton driven and
peptide driven counterﬂow assays, reconstituted variants of both trans-
porters in liposomes were assayed for their ability to uptake [3H]-di al-
anine [51]. The results of these studies are shown in Fig. 6A for the
equivalent residues seen in the binding pocket of PepTSt. Mutation of
Glu22 (32), Glu25 (35), Arg26 (36) or Tyr30 (40) (GkPOT numbering
in parentheses) to alanine resulted in transporter variants that could
no longer transport under proton driven conditions but could still rec-
ognize and transport peptide during counterﬂow [51]. Within the N-
terminal bundle only one residue was found to abolish transport in
both assays, Arg33 (43), which as we discuss below is likely to play an
important role in regulating the interaction between TM1 and TM7 as
part of the extracellular gate and potentially in controlling the proton-
ation state of Glu300 (Glu310). On theC-terminal side of the transporter
all the conserved residues assayed produced transport deﬁcient pro-
teins, indicating the C-terminal bundle is more sensitive to mutation.
4. Tyrosine residues regulate peptide speciﬁcity
The peptide-binding site contains three prominent tyrosine side
chains that are conserved within the PTR family (Fig. 1). In PepTSt
these are Tyr29 and Tyr30 onTM1and Tyr68on TM2(Fig. 6A).Mutation
of Tyr30 to phenylalanine resulted in loss of proton driven peptide
BA
Fig. 6. Peptide binding site. A. Zoomed in view of the central cavity in PepTSt, with the helices represented as cylinders and shown in the plane of the membrane. Side chains observed
within the cavity are labeled, with the equivalent residue numbers for GkPOT shown in parenthesis. The function of these residues determined from in vitro assays is indicated.
B. Table showing the calculated IC50 values for different peptides in the WT and Y29F and Y68F variants of PepTSt.
494 S. Newstead / Biochimica et Biophysica Acta 1850 (2015) 488–499uptake but retention of counterﬂow transport, suggesting this residue
plays an important role in the proton coupling mechanism [49].
Supporting this role, mutation of Tyr30 to alanine resulted in complete
loss of transport in PepTSt and GkPOT [51]. In contrast the hydroxyl
groups of both Tyr29 and Tyr68 do not contribute to proton binding in
PepTSt, as their mutation to phenylalanine had little impact on proton
driven uptake [49].
To investigate the role of Tyr29 and Tyr68 further a series of compe-
tition experimentswere performedwith a library of di- and tri-peptides
(Fig. 6B). The phenyalanine mutants showed distinct changes in their
afﬁnity for di-Glu and tri-Ala peptides compared to the WT protein,
with the alaninemutants losing their ability to transport these peptides
altogether while still retaining afﬁnity for di-Phe and di-Ala peptides.
This difference suggested Tyr29 andTyr68 are important in determining
peptide speciﬁcity, which appears to be supported by the interactions
these side chains make to the alafosfalin peptide in the GkPOT and
PepTSo2 structures. To quantify the contribution made by Tyr29 and
Tyr68 to peptide afﬁnity, IC50 values for these peptides were calculated
for each of the phenylalanine mutants. The Tyr29Phe mutant had a de-
creased afﬁnity for tri-alanine, IC50 of 1.4 mM compared with 0.4 mM
for the WT, while still retaining WT afﬁnity levels for di-Glu. The
Tyr68Phe mutant displays a decreased afﬁnity for di-Glu, IC50 valuesof 1.63mM compared with 0.56mM for theWT protein while retaining
the same afﬁnity for tri-alanine. Taken together, these results support
the importance of the conserved tyrosine residues in peptide recogni-
tion, in agreement with previous studies on the mammalian PepT1
transporter [23,62].
5. Salt bridge interactions orchestrate communication between the
N- and C-terminal bundles during transport
To mediate peptide transport across the membrane the PTR trans-
porters must undergo substantial conformational change to enable the
central peptide binding site to be alternately exposed to either side of
the membrane [45]. These structural changes are often described in
terms of the opening and closing of ‘gates’, or localized areas of the pro-
tein that either restrict or allow access to the ligand and driving ions to
their respective binding sites (reviewed in [46]). In the PTR family the
recent crystal structures have allowed identiﬁcation of the extracellular
gate [40,49]. Homologymodeling on the outward facing structure of the
fucose:proton symporter FucP has further allowed speculation on the
nature of the intracellular gate. The extracellular gate is constructed
from TM1 and TM2 in the N-terminal bundle and helices TM7 and
TM8 in the C-terminal bundle, which in all current PTR structures
Fig. 7. Structural comparison between PepTSo and PepTSt revealed the nature of the extracellular and intracellular gates. Centre of theﬁgure shows a slice through the volume of PepTSo and
PepTSt positioned as in Fig. 3 & 4 for GkPOT and PepTSo2 respectively. Key structural regions discussed in the text are illustrated. Top left, zoomed in view of the extracellular gate region in
PepTSo, illustrating the salt bridge interaction between Arg32 on TM1 and D316 on TM7 and their position with respect to the extracellular cavity. Top right, zoomed in view of the equiv-
alent region in PepTSt, showing the proximal and distal salt bridges stabilizing the interaction between helices TM1, TM2 from the N-terminal and TM7, TM8 from the C-terminal bundles
respectively.
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peptide-binding site. In PepTSt these are Arg53 (TM1) with Glu312
(TM7), which forms distal to the central peptide binding site and
Arg33 (TM1) with Glu300 (TM7), which forms directly above the bind-
ing cavity andwhichwehave called theproximal salt bridge (Fig. 7 right
hand side). In GkPOT the equivalent residues are Arg43 (TM1) and
Glu310 (TM7) at the proximal salt bridge, although in the alafosfalin
complex these are not making a direct interaction due to the presence
of the peptide and the interaction of the phosphono group with
Glu310. In comparison, PepTSo only has the proximal salt bridge formed,
between Arg31 (TM1) and Asp316 (TM7), the distal salt bridge being
broken, presumably as a result of adopting a more occluded state
(Fig. 7 left hand side). Whereas in PepTSo2 only the distal salt bridge is
present, between Asp47 and Arg304. Notice that the charges have
swapped in PepTSo2, which is also observed in GkPOT, where Glu63
(TM1) and Lys322 (TM7) form the distal salt bridge.
In both PepTSt mutation of Glu300 to alanine abolished uptake in
both a proton driven and peptide driven counterﬂow assay, whereas
transport in the Arg33 mutant was only abolished in the proton driven
assay [49,51]. In GkPOT equivalent mutations resulted in similar trans-
port results [49,51]. These results suggest that Arg33 has an important
role in facilitating proton coupling but does not affect peptide recogni-
tion. In contrast the conserved glutamate on TM7, Glu300 appears es-
sential for peptide recognition, a role also supported by the crystal
structure of GkPOT complexed with alafosfalin.
This result suggests a functional subdivision of labor between the
two residues at this structurally important region of the transporters.
However, for any mechanism to be coupled, one component must rely
on the other for function. The result obtained from these assays suggeststhat these two residues have important complementary roles in proton
binding and peptide transport. Clearly the identiﬁed salt bridge interac-
tions between Arg33–Glu300 (PepTSt) and Arg43–Glu310 (GkPOT) par-
ticipate in both proton binding and peptide transport and facilitate
closure of the extracellular gate region. As discussed below, we propose
these interactions play an important role in orchestrating alternating
access within members of the POT family. However, the structure of
PepTSo2 raises an interesting conundrum, as this apparently important
salt bridge interaction is not present, with no obvious alternative substi-
tute (Fig. 4). However, there is an interaction between the equivalent
residues, Gln32 (TM1) and Ser325 (TM7), but this is unlikely to operate
in the same way as the salt bridge present in the other members of the
PTR family.
6. A possible induced ﬁt mechanism for peptide transport
The binding of ligands to proteins often results in structural changes
that promote interaction between side chains and the ligand in the
binding site. The accumulation of structures from different PTR family
members now allows for a useful structural comparison to be made.
Prior to the publication of the alafosfalin studies, a comparison between
the occluded PepTSo structure and inward open PepTSt revealed that he-
lices in the C-terminal bundle moved away from their respective posi-
tions in the occluded state to open up the central binding site (Fig. 8A)
[49]. We observed that this movement was predominantly localized to
the cytoplasmic ends of TM10 and TM11, such that the apex of these he-
lices swung away from their symmetrically opposed opposite counter-
parts, TM4 and TM5. The resulting conformational change caused side
chains that had previously blocked exit of the unknown ligand in PepTSo
A B
Fig. 8. Intracellular gate mechanism. A. Comparison between the inward open PepTSt (gray helices) and occluded PepTSo structure (colored helices) with arrows showing the hinge like
movement that opens the intracellular gate. View is from the membrane plane. Residues forming the intracellular gate are shown as stickmodels with transparent CPK surfaces. Residue
numbers are for PepTSt. The peptide-binding site containing Lys127 and Glu419 is indicated and alafosfalin modeled in the position occupied in the GkPOT structure. TM11 of PepTSo2 is
also shown (dark gray) although in this case the movement of TM11 was more pronounced. B. The occlusion of peptide in the binding site appears to form via an induced ﬁt mechanism
with TM4–5 and TM10–11 closing in around the peptide (blue arrows). The four TM helices forming the intracellular gate are colored red. This movement is facilitated by conserved
proline residues identiﬁed in the MD simulations as being important for the closing of TM4–5 in GkPOT and a conserved glycine and tryptophan residue in TM10 and TM11 respectively
that facilitate the reciprocal movement in these helices illustrated in A. The alafosfalin peptide is shown in sticks.
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way from the binding site to the cytoplasm. Structural comparison with
PepTSo2 revealed a similar movement likely occurs in this transporter
[52], albeitwith a slightly different trajectorywith TM11moving further
away than observed in PepTSt. This movement would also result in the
closing of the smaller extracellular cavity observed in the PepTSo struc-
ture (Fig. 7), and lends support to our earlier hypothesis that helices
within the C-terminal bundle are likely to be more dynamic during
transport than their N-terminal counterparts.
To analyze the effects of protonation and peptide binding on the dy-
namics of PTR family transporters, a molecular dynamics (MD) study
was conducted on GkPOT in the presence of a POPC lipid bilayer [51].
In 200 ns simulations run in the apo state, the models where Glu310
was protonated remained stable in the bilayer, with rms ﬂuctuations
of ~1.0 Å between the N- and C-terminal bundles. Interestingly, when
Glu310 was deprotonated the same simulation set up resulted in sub-
stantial structural changes, with the cytoplasmic half of helices TM4
and TM5 moving in towards TM8 and bending at two conserved pro-
lines, Pro137 (TM4) and Pro173 (TM5). The result of this movement
was to occlude a placed di-phenylalanine peptide in the binding site
(Fig. 8B). The structural movement observed is very similar to that de-
scribed above for the C-terminal helices TM10–11, suggesting that dur-
ing peptide binding the transporter closes up around the peptide
through the movement of individual helices, consistent with a recent
analysis of other MFS structures [63,64] and resembling an induced ﬁt
mechanism of binding. During the simulation, the movement reversed,
suggesting that these two states are in equilibrium.
During the structural transition to the partially occluded state, the
interaction between Arg43 on TM1 and Glu310 on TM7 in GkPOT is
seen to form. This observation suggests that during the simulation
Glu310 must lose the proton initially placed at the start of the simula-
tion. Indeed, it was speculated by Doki et al., that the observed interac-
tion of Arg43 might cause the deprotonation of Glu310 through a
modulation of the pKa of the side chain [51]. This suggestion certainlyseems an appealing way to couple the structural rearrangement of the
extracellular gatewith the release of a proton from a side chain involved
in peptide recognition. However, further studieswill be required to con-
ﬁrm this model.
In the MD simulation with the di-phenylalanine peptide, the C-
terminal phenyl side chain formed hydrophobic interactions with
Tyr78, Trp306 and Trp440 (Fig. 3), appearing to induce the formation
of a deﬁned hydrophobic pocket within the binding site [51]. Such hy-
drophobic pockets have previously been reported for the OppA proteins
[65] and help to orientate peptides within the binding surface of these
proteins. Similar hydrophobic pockets were also predicted to form
within PepTSo [40] and the binding site of PepT1. Overall the crystal
structures of both the GkPOT sulfate and alafosfalin complexes com-
bined with the MD simulations suggest that protonation and de-
protonation of Glu310may have an important role to play in orchestrat-
ing the conformational rearrangements required for transport. The
structural comparison with the other PTR family members and the dy-
namic nature of the molecule in the MD simulations also suggests that
the structural rearrangements that orientate the binding site in re-
sponse to proton and peptide binding are the result of nuanced move-
ments in TMs1, 2, 4, 5 from the N-terminal bundle and TMs7, 8, 10, 11
from the C-terminal bundle.
7. A mechanism for proton coupled transport within the PTR family
A large body of experimental data collected on the lactose permease,
LacY from E. coli, has led to a clearer picture emerging for the role of pro-
tons in the sugar:proton symporters [66]. During uphill transport, or the
protein working under physiological conditions of lactose accumula-
tion, protonation is required for LacY to bind lactose, whereupon it is
the energy of sugar binding and dissociation into the interior of the
cell that is predicted to drive the conformational changes that result in
transport [67,68]. During release of ligand, sugar dissociates ﬁrst, caus-
ing a conformational change that results in deprotonation into the
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TM9 to Glu325 on TM10 during lactose transport causes de protonation
from the latter side chain [69]; a functional equivalent of which is pres-
ent in all structures of sugar:proton symporters determined to date [66].
Reorientation of the empty carrier is driven by re protonation from the
exterior of the cell.
Given this ordered kinetic scheme, canwemake sense of the current
experimental data for the PTR family? The proposed de protonation of
Glu310 by Arg43 in GkPOT discussed above is similar to that proposed
in the sugar:proton symporters. A similar mechanism may therefore
exist for the PTR family, where proton binding in the outward facing
state precedes peptide binding, whereupon the energy released during
peptide binding is used to drive the conformational change that re ori-
entates the binding site during transport. However, in the case of LacY
the sugar binding site does not exist in the absence of ligand in the in-
ward open state [70], whereas comparisons between apo and peptideA
D
Fig. 9. Amodel for proton driven peptide symport in the PTR family. A. An outward facing state,
chosen at the start of the cycle. This state is characterized by the packing of helices TM4–5with
interaction between K136 and E413 (GkPOT numbering). B. Peptide (here illustrated by the ala
side of themembrane. The conserved glutamate on TM7 (E310) is where present likely to play
important roles in proton binding for the N-terminal ExxERFxYY motif on TM1 and K136 in TM
binding site play important roles in peptide recognition and speciﬁcity. C. Binding results in c
structure. This conformation is characterized by the packing of helices TM7–8 against TM1–2 at
interactions between R43 and E310 and by the distal salt bridge between TM2 and TM7 (not sh
between K136 and E413, thereby facilitating release of the intracellular gate. In the occluded s
closure of the extracellular gate, as observed in the occluded PepTSo structure. D. Transition to
TM4–5 and TM10–11 that results in release of the intracellular gate, allowing exit of proton and
of the salt bridge between R43 and E310 is very likely to result in release of the proton from E31
the intracellular gate helices and ejection of the peptide and proton into the interior of the cellbound GkPOT reveal little structural difference, suggesting the binding
site is present in this case [51].
A preliminary mechanism for proton coupled peptide uptake within
the PTR family is presented in Fig. 9 using side chain numbering from
GkPOT (Figs. 1 & 3). In this scheme the outward facing and inward fac-
ing states are symmetrical and quite possibly energetically equivalent.
Our current understanding of the structures and identiﬁcation of the
gates within the PTR family now reveal that movement between out-
ward and inward open states is very likely composed of many smaller
helical rearrangements within functional sub-bundles of helices with
each of the N- and C-terminal domains rather than large rigid
body movements as previously thought. In the outward open state
(Fig. 9A), the intracellular gate is constructed from TM4, TM5 packing
against helices TM10, TM11and stabilized through a putative salt bridge
between Lys136 (TM4) and Glu413 (TM10) [49]. The extracellular gate,
constructed from TM1, TM2 and TM7, TM8 remain apart and open.B
C
heremodeled on the outward facing fucose permease structure (PDB: 3O7Q) is arbitrarily
TM10–11 that form the intracellular gate and is potentially stabilized through a salt bridge
fosfalin peptide in magenta sticks) and proton H+ (red circle) bind from the extracellular
an important role in proton binding, whichmust facilitate entry of the peptide. Additional
4 are also suggested by the functional data on PepTSt. Conserved tyrosine residues in the
losure of the extracellular gate to form the occluded state, here modeled on the occluded
the extracellular side of the binding site, assisted through the formation of the salt bridge
own). Binding of both peptide and proton is also likely to disrupt the proposed interaction
tate an additional extracellular cavity may also form in the C-terminal domain following
the inward facing state occurs in part through localized hinge-like movement in helices
peptide into the interior of the cell. The closing of the extracellular gate and the formation
0 and this is likely to be coupled to the conformation changes that result in the opening of
.
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can enter the binding site (Fig. 9B), whereupon TM1, TM2 and TM7,
TM8 begin to close around the peptide (Fig. 9C). This movement is
very likely reinforced through the establishment of an electrostatic in-
teraction between the proximal salt bridge between Arg 43 (TM1) and
Glu310 (TM7) observed in the crystal structures. This movement must
then couple with the weakening and eventual breaking of the intracel-
lular salt bridge, which must result in the peeling away of helices TM4,
TM5 from TM10, TM11. This is most likely achieved through an inter-
mediate state similar to the crystal structure of PepTSo and resulting in
the release of bound proton and peptide into the interior of the cell
(Fig. 9D). Particularly interesting with respect to the proposed model
is the role of the inverted symmetry repeats within both of the 6-TM
bundles [71]. In this model, the ﬁrst repeat from each bundle contrib-
utes to the extracellular gate, whereas the second repeat contributes
to the intracellular gate, with two helices acting as support units, TM3,
TM6 in theN-terminal bundle and TM9, TM12 in the C-terminal bundle.
This produces a blueprint for alternating access within the PTR family
that places helices TMs1, 2, 4, 5 and TMs7, 8, 10, 11 in dynamic equilib-
riumbetween two presumably energetically equivalent states and TM3,
6, 9 and 12 acting as support rods, as suggested for GlpT, the glycerol-3-
phosphate transporter from E. coli [71].
8. Future perspectives
Recent advances in the structural biology and biochemistry of bacte-
rial PTR family transporters has signiﬁcantly impacted our understand-
ing of themolecular basis for transport in this family [26]. However, key
questions remain to be addressed, particularly with respect to peptide
speciﬁcity. While information on the role of the conserved tyrosine res-
idues hints at some discrimination, recent evidence from the E. coli PTR
transporter YjdL suggests that in this case, single amino acids and even
tetra-peptides can be transported in a proton dependent manner [72].
Clearlymore still remains to be uncovered. Another area of interest con-
cerns the oligomeric state of PTR members. PepTSo2 was reported to
exist as a tetramer in detergent [52],with the suggestion that this higher
oligomeric state may have some role in the regulation of transport
in vivo. Further studies will be required to address this question for
the other PTR members to determine if higher oligomeric complexes
are an important part of their physiological state in the membrane.
However, with respect to understanding the molecular basis of drug
transport through these systems, the most important goal is to tackle
the mammalian targets, PepT1 and PepT2. It is highly likely in this
author's opinion that important differences will exist in themechanism
of these proteins compared with their bacterial counterparts. An obvi-
ous one is the large extracellular domain present between TM9 and
TM10 in PepT1 and PepT2 (Fig. 1) that is absent in the bacterial, fungal
and plant homologues. Ultimately it will be the determination of their
structure and further biochemical investigations that will delineate
these differences and reveal the full complexity of this extraordinary
transporter family.
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